KHB(SZ:002022) Sou Hu Cai Jing·2025-05-06 08:52Group 1 - The core viewpoint of the news is that Kehua Bio's stock has experienced a decline in performance, with a significant drop in revenue and net profit in the latest quarterly report [1] - As of May 6, Kehua Bio's closing price was 5.76 yuan, up 1.41%, with a market-to-book ratio of 0.91, marking a new low in 20 days and a total market value of 2.962 billion yuan [1] - The company reported a revenue of 388 million yuan for Q1 2025, a year-on-year decrease of 12.50%, and a net loss of approximately 53.26 million yuan, a year-on-year decline of 84.79%, with a gross profit margin of 37.39% [1] Group 2 - Kehua Bio's main business includes the research, production, and sales of in vitro diagnostic reagents and medical testing instruments, with key products in biochemical diagnosis, immunodiagnosis, and molecular diagnosis [1] - The company has received several honors, including the National Science and Technology Progress Award (Second Class), and is recognized as a national high-tech enterprise and a pilot enterprise for intellectual property [1] - In comparison to industry averages, Kehua Bio's price-to-earnings ratio (TTM) is -4.45, and its market-to-book ratio is 0.91, indicating a lower valuation compared to the industry average [2]